Alissa Huston

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi Role of the microenvironment in multiple myeloma bone disease
    Alissa Huston
    University of Pittsburgh Cancer Institute, and VA Pittsburgh Healthcare System, Research and Development, PA 15240, USA
    Future Oncol 2:371-8. 2006
  2. ncbi Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma
    Lanie K Francis
    University of Pittsburgh Cancer Institute, Division of Hematology/Oncology, Department of Internal Medicine, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 12:6826-35. 2006
  3. ncbi Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma
    Alissa Huston
    Exp Hematol 34:1616. 2006
  4. ncbi Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment
    Alissa Huston
    James P Wilmot Cancer Center, University of Rochester, Rochester, New York, USA
    Clin Cancer Res 14:865-74. 2008
  5. ncbi Involvement of hepcidin in the anemia of multiple myeloma
    Sanjai Sharma
    West Los Angeles VA University of California Los Angeles Medical Center, Los Angeles, CA 90073, USA
    Clin Cancer Res 14:3262-7. 2008

Collaborators

Detail Information

Publications5

  1. ncbi Role of the microenvironment in multiple myeloma bone disease
    Alissa Huston
    University of Pittsburgh Cancer Institute, and VA Pittsburgh Healthcare System, Research and Development, PA 15240, USA
    Future Oncol 2:371-8. 2006
    ....
  2. ncbi Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma
    Lanie K Francis
    University of Pittsburgh Cancer Institute, Division of Hematology/Oncology, Department of Internal Medicine, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 12:6826-35. 2006
    ..CONCLUSIONS: These studies provide the basis for potential clinical evaluation of this combination for multiple myeloma patients...
  3. ncbi Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma
    Alissa Huston
    Exp Hematol 34:1616. 2006
  4. ncbi Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment
    Alissa Huston
    James P Wilmot Cancer Center, University of Rochester, Rochester, New York, USA
    Clin Cancer Res 14:865-74. 2008
    ....
  5. ncbi Involvement of hepcidin in the anemia of multiple myeloma
    Sanjai Sharma
    West Los Angeles VA University of California Los Angeles Medical Center, Los Angeles, CA 90073, USA
    Clin Cancer Res 14:3262-7. 2008
    ..Because interleukin (IL)-6 is a potent inducer of hepcidin expression and its levels are elevated in multiple myeloma, we studied the role of hepcidin in the anemia of multiple myeloma...